Ionis Pharmaceuticals (IONS) Receivables - Other (2017 - 2026)

Ionis Pharmaceuticals' Receivables - Other history runs 10 years deep, the most recent figure standing at $58.8 million for Q2 2026.

• In Q2 2026, Receivables - Other rose 11.92% year-over-year to $58.8 million; the TTM figure through Jun 2026 stood at $58.8 million (up 11.92% YoY), while the FY2025 annual figure was $66.1 million, down 28.34% from the prior year.
• Receivables - Other for Q2 2026 stood at $58.8 million, down from $73.7 million in the prior quarter.
• The five-year high for Receivables - Other was $142.4 million in Q3 2023, with the low at $5.1 million in Q1 2024.
• The 5-year median for Receivables - Other is $27.6 million (2023), against an average of $44.7 million.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other surged 2042.35% in 2023, then plunged 87.41% in 2024.
• Ionis Pharmaceuticals' Receivables - Other stood at $25.5 million in 2022, then soared by 282.87% to $97.8 million in 2023, then decreased by 5.72% to $92.2 million in 2024, then slipped by 28.34% to $66.1 million in 2025, then slipped by 10.92% to $58.8 million in 2026.
• Business Quant data shows IONS's Receivables - Other at $58.8 million in Q2 2026, $73.7 million in Q1 2026, and $66.1 million in Q4 2025.